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Breimmune fetal sheep, resulted in up to 5% human hematopoietic
ngraftment. More than 20% albumin-producing human paren-
hymal hepatic cells with absence of cell fusion as well as substan-
ial numbers of human cardiomyocytes in both atria and ventricles
f the sheep heart were detected still over one year following
SSC transplantation. No malignant cell transformation was ob-
erved in any of these animals.
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ORD BLOOD CRYOBIOLOGY: IMPACT ON TRANSPLANT OUTCOMES
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ersity, St. Louis Cord Blood Bank, St. Louis, MO.
The therapeutic potential of cord blood (CB) for hematopoietic
tem/progenitor cell (HSC) transplantation is primarily limited by
he number (dose) of functionally viable HSC administered to the
ransplant recipient. The process of cryopreservation and thawing
f CB products is the single greatest and most variable source of
SC loss from collection to infusion and the effects of cryopreser-
ation and thaw on CB HSC function are inherent in all published
omparisons of CB versus BM or PBSC transplant outcome. We
erformed a series of studies to examine the effects of cooling rate
CR) and type of cryoprotectant (DMSO, propanediol) on CB
SC cell number (TNC and CD34), viability (trypan blue,
-AAD) and function (CFU assay) post-thaw. Varying the CR
rom 1 to 20 deg. C/min. had little effect on recovery (%) of
B HSC number and trypan blue viability (%), however, CB HSC
unction (CFU recovery (%)) decreased markedly at CR above 5
eg. C/min. Monitoring of the CR of cord blood units is subject to
rtifacts arising from alterations in thermistor probe placement
ecessitating careful review of cooling curves and on-site validation
f the cryopreservation system. Frozen CB units placed in liquid
2 must occasionally be transferred to other locations or tempo-
arily removed from liquid N2 for retrieval of attached segments
xposing the unit to potential warming effects (PWE). Transfer of
B units in Styrofoam containers with liquid N2 or segment
emoval in liquid N2 vapor does not cause any detectable loss of
SC number, viability or function. Similarly, repeated exposure of
rozen CB units to 10 consecutive 1 min. intervals at room tem-
erature also had no signiﬁcant effect on HSC number, viability or
unction. We conclude that transient warming during CB unit
ransfer or segment removal does not result in measurable PWE.
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How is cord blood regulated?
In response to the initiative to “reinvent” the regulation of
uman tissue, the FDA published the Proposed Approach to Reg-
lation of Cellular and Tissue-Based Products (Federal Register
/28/1997). To implement this approach, three new rules are to be
odiﬁed in 21 CFR 1271:
Establishment Registration and Listing
Donor Eligibility
Current Good Tissue Practices (cGTP)
All manufacturers of human cells, tissue, and cell and tissue-based
roducts (HCT/P), including cord blood, will be required to com-
ly with these regulations when ﬁnalized. HCT/Ps that have a
etabolic function such as cord blood require additional controls;
hese products are also regulated as biologics under the authority of
ection 351 of the Public Health Service Act.
Cell or tissue products requiring FDA premarket approval meet
ny of the following criteria:
● Expanded, activated, genetically modiﬁed or otherwise more
han minimally manipulatedB&MT● Combined with a drug or device, with some exceptions
● Labeled or advertised for non-homologous use, such as HPC
elivered for cardiac repair
● Clinical effect is systemic or dependent upon the metabolic
ctivity of the cells, except if for autologous use, or use in a ﬁrst or
econd-degree blood relative. Example: allogeneic, unrelated do-
or cord and peripheral blood stem/progenitor cells
Phase-in of FDA approval requirements for some hemato-
oletic progenitor cell products (HPC)
Allogeneic unrelated minimally manipulated HPC for hemato-
oietic reconstitution require assurance of clinical safety and ef-
ectiveness. Cord blood and peripheral blood stem/progenitor cell
roducts from unrelated donors are subject to “phase-in” of IND
nd licensure requirements. As described in the Federal Register
otice entitled “Request for Proposed Standards for Unrelated
llogeneic Peripheral and Placental/Umbilical Cord Blood Hema-
opoietic Stem/Progenitor Cell Products; Request for Comments”
ublished 1/20/1998, standaros may be developed for these HPC
roducts if data exist to show safety and effectiveness when man-
factured in accordance with certain deﬁned product speciﬁcations
nd process controls.
Finalization and Implementation of 21 CFR Part 1271: cur-
ent status
Finalizing the three rules that together will be codiﬁed as 21 CFR
art 1271 is a current FDA priority. The establishment registra-
ion and listing ﬁnal rule was published in January 2001. The
stablishment registration and listing interim ﬁnal rule, published
n January 2004, explains that all HCT/P establishments are now
equired to register and list as of March 29, 2004, with the excep-
ion of those manufacturing human heart valves and dura mater.
his interim rule will be revoked when all of Part 1271 becomes
ffective.
The ﬁnal donor eligibility rule was published on May 25, 2004,
nd becomes effective on May 25, 2005. It is accompanied by draft
uidance that provides recommendations for complying with the
equirements in the donor eligibility rule. Comments on the draft
uidance should be received by August 23, 2004 (90 days from the
ublication date) to ensure consideration in the ﬁnal guidance. The
ule is available on FDA’s website at www.fda.gov/OHRMS/
OCKETS/98fr/97N-484S-nfr0001.pdf and the guidance is
vailable at www.fda.gov/cber/gdlns/tissdonor.pdf. Publication of
he ﬁnal GTP rule is expected soon. The changes to the ﬁnal rules
ddress many of the concerns raised by cell therapy and blood bank
rofessional associations and establishments, submitted as com-
ents to the docket.
Possible issues for international exchange with the U.S.
Non-U.S. manufacturers are required to annually register with
DA if their HPC products are used in the U.S. These manufac-
urers must complete the form 3356 and indicate a U.S. Agent. All
onor testing must be performed in CLIA accredited laboratories
sing FDA cleared/approved test kits. Currently there are more
han 40 registered HPC facilities outside of the U.S.
Summary
Implementation of the regulatory approach to human cell and
issue products is nearing completion. The period of enforcement
iscretion for unrelated donor cord blood is ongoing, pending
etermination of whether there are adequate data to support a
tandards-based approach to licensure. Cord blood manufacturers
urrently must register with the FDA, and will be required to
omply with DE and GTP requirements when ﬁnalized and effec-
ive.
Information Available
The website at www.fda.gov/cber/tiss.htm has links to the down-
oadable Form 3356 (Registration/listing), all published documents
nd letters; and relevant meeting minutes, summaries, transcripts,
nd presentations. The e-mail address for registration questions is
issuereg@cber.fda.gov.739
